3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
14
Breast Cancer Metastatic
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
HR Positive HER2 Negative Advanced Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
4
trastuzumab deruxtecan
2
elacestrant
2
Vinorelbine
2
toripalimab
1
talazoparib
1
ribociclib
1
pyrotinib
1
palbociclib
1
olaparib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
apatinib
1
abemaciclib
1
Selective Estrogen Receptor Modulators
1
Ritonavir
1
Radiotherapy
1
RAD1901
1
Letrozole
1
Itraconazole
1
Injections
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Capecitabine
1
Aromatase Inhibitors
1
Anastrozole
1
Ado-Trastuzumab Emtansine
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Advanced Breast Cancer
×
dalpiciclib
×
Clear all
NCT06301438
2026-02-03
Dalpiciclib in HR+/HER2- ABC
RenJi Hospital
Recruiting
103 enrolled